Das HAS? New French comparator plan echoes German reimbursement
This article was originally published in Scrip
The French HTA agency, the HAS (Haute Autorité de Santé), has published details of a new "relative therapeutic index" mechanism that it plans to use to select medicines for reimbursement on the basis of a comparison with existing products.
You may also be interested in...
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.